Validation of a Screening Scale for Misuse of Opioid Analgesics (VPOMIONCOL)

November 13, 2026 updated by: University Hospital, Clermont-Ferrand

Validation of a Screening Scale for the Misuse of Opioid Analgesics in Patients With Chronic Pain Related to Cancer.

In oncology, pain is one of the main symptoms of discomfort. It has a significant impact on the quality of life.The use of opioid analgesics is recommended for the treatment of moderate to severe cancer pain.The misuse of opioid analgesics is an international public health problem.Different scales have been developed to help the prescriber screen for the risk of misuse in the general population. Patients with cancer-related pain are also at risk for aberrant opioid-related behaviors, misuse or addiction.

The main objectif of this study is to validate of the screening scale for the misuse of opioid analgesics in patients with chronic pain related to cancer. (Prescription Opioid Misuse Index - POMI).

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The study takes place in 2 phases.

Test phase :

Questionnaire no. 1 constitutes the data for the TEST phase: it includes socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Concise Pain Questionnaire (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.

Retest phase :

questionnaire no. 2 10 to 15 days later.

Study Type

Observational

Enrollment (Actual)

138

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Clermont-Ferrand, France
        • CHU de Clermont-Ferrand
      • Le Puy-en-Velay, France, 43000
        • CH Le Puy en Velay

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Cancer patients

Description

Inclusion Criteria:

  • Patients aged 18 and over,
  • Patients with chronic cancer-related pain that has been evolving for at least 3 months,
  • Patients with a regular prescription of at least one opioid analgesic medicine taken daily for at least 1 month,
  • Patients followed in oncology for an active cancerous pathology.

Exclusion Criteria:

  • Stopping opioid prescriptions on the day of the test phase (no Retest possible),
  • Patients in the process of weaning (risk of being weaned during the Retest phase),
  • Patients unable to complete the questionnaire on their own,
  • Patients followed in a pain or addiction centre,
  • Patients in terminal palliative situations of their cancer,
  • Patients with chronic pain that is more disabling than cancer-related pain,
  • Patients refusing to participate,
  • Patients under guardianship or curatorship,
  • Pregnant or breastfeeding patients,
  • Patient with a language barrier limiting understanding of the questionnaire in French.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
cancer patients

Questionnaires

questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
POMI scale score - Prescription Opioid Misuse Index
Time Frame: day 1

8-item self-assessment scale

day 1
POMI scale score - Prescription Opioid Misuse Index
Time Frame: day 15

8-item self-assessment scale

day 15

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QCD
Time Frame: day 1

Visual Analogue Scales (VAS) for assessing the intensity and daily impact of pain (0-10)

day 1
QCD
Time Frame: day 15

Visual Analogue Scales (VAS) for assessing the intensity and daily impact of pain (0-10)

day 15
Sociodemographic characteristics
Time Frame: day 1

Questionnaire about Sociodemographic characteristics of patients

day 1
Lifestyle habits, other consumption
Time Frame: day 1

Questionnaire about Lifestyle habits, other consumption

day 1
Analgesic treatments
Time Frame: day 1

Questionnaire about Ongoing analgesic treatments

day 1
Use of analgesics
Time Frame: day 1

Question evaluating the use of analgesics in the context of anticipating pain

day 1
Use of analgesics
Time Frame: day 15

Question evaluating the use of analgesics in the context of anticipating pain

day 15

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Virginie Guastella, University Hospital, Clermont-Ferrand

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 23, 2023

Primary Completion (Actual)

December 30, 2024

Study Completion (Actual)

June 30, 2025

Study Registration Dates

First Submitted

February 16, 2023

First Submitted That Met QC Criteria

February 27, 2023

First Posted (Actual)

March 9, 2023

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

February 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe